Free Trial

Cara Therapeutics (TVRD) Competitors

$30.95 -2.44 (-7.31%)
As of 03:19 PM Eastern

TVRD vs. ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, and CELUW

Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry.

Cara Therapeutics vs.

180 Life Sciences (NASDAQ:ATNFW) and Cara Therapeutics (NASDAQ:TVRD) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
Cara Therapeutics N/A N/A N/A

In the previous week, Cara Therapeutics had 4 more articles in the media than 180 Life Sciences. MarketBeat recorded 5 mentions for Cara Therapeutics and 1 mentions for 180 Life Sciences. 180 Life Sciences' average media sentiment score of 1.89 beat Cara Therapeutics' score of 0.58 indicating that 180 Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
180 Life Sciences Very Positive
Cara Therapeutics Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
Cara TherapeuticsN/AN/AN/AN/AN/A

44.7% of Cara Therapeutics shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cara Therapeutics received 1 more outperform votes than 180 Life Sciences when rated by MarketBeat users.

CompanyUnderperformOutperform
180 Life SciencesN/AN/A
Cara TherapeuticsOutperform Votes
1
50.00%
Underperform Votes
1
50.00%

Cara Therapeutics has a consensus target price of $65.00, suggesting a potential upside of 94.67%. Given Cara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cara Therapeutics is more favorable than 180 Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
180 Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Cara Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Cara Therapeutics beats 180 Life Sciences on 7 of the 8 factors compared between the two stocks.

Get Cara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVRD vs. The Competition

MetricCara TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$104.01M$6.51B$2.03B$8.46B
Dividend YieldN/A2.65%2.64%4.17%
P/E RatioN/A8.7722.6519.89
Price / SalesN/A255.5157.95138.43
Price / CashN/A65.8551.7234.64
Price / BookN/A6.422.084.56
Net IncomeN/A$142.98M-$292.00M$248.06M
7 Day PerformanceN/A3.41%0.74%2.14%
1 Month PerformanceN/A2.10%6.91%9.07%
1 Year PerformanceN/A-0.68%15.68%9.74%

Cara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVRD
Cara Therapeutics
N/A$30.95
-7.3%
$65.00
+110.0%
N/A$96.41MN/A0.0080News Coverage
High Trading Volume
ATNFW
180 Life Sciences
N/A$0.01
+1.4%
N/A-16.8%$0.00N/A0.007
LBPSW
4D pharma
N/AN/AN/AN/A$0.00$522,000.000.00N/A
AEHAW
Aesther Healthcare Acquisition
N/A$0.01
flat
N/A-91.2%$0.00N/A0.002Gap Up
AIMDW
Ainos
N/A$0.21
+48.9%
N/A+71.6%$0.00$106,207.000.0040
ALVOW
Alvotech
N/A$1.80
flat
N/A-32.4%$0.00$585.60M0.004
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.01
-0.8%
N/A-78.9%$0.00N/A0.0015Gap Up
High Trading Volume
BFRIW
Biofrontera
N/A$0.09
-18.1%
N/A+72.0%$0.00$38.00M0.0070Gap Down
BTMDW
biote
N/A$0.02
flat
N/A-94.5%$0.00$199.38M0.00N/A
BCTXW
BriaCell Therapeutics
N/A$0.10
-4.6%
N/A-82.2%$0.00N/A0.008
CELUW
Celularity
N/A$0.04
-33.3%
N/A+54.2%$0.00$54.22M0.00220Gap Down

Related Companies and Tools


This page (NASDAQ:TVRD) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners